




TauRx's mission is to discover, develop and commercialise innovative products for the diagnosis, treatment and cure of neurodegenerative diseases caused through protein aggregation.

The Time for Tau is Now



TauRx



Foreword

The foundation of TauRx really began when I finished medical school and did my PhD at Cambridge, under the supervision of Sir Martin Roth. He tasked me with a project to discover what the Alzheimer tangle was composed of. In 1988, the results of this research found the tangles were made up of tau proteins clumped together. My discovery that these tangles could be dissolved by a type of chemical was quite by accident but became the catalyst for decades of research to try to develop an effective treatment for Alzheimer's and other neurodegenerative diseases.

TauRx was founded in Singapore 2002 with the support of colleagues at University of Aberdeen and the Charité Institute, Berlin, with the aim of developing the core science to support research into new treatments and diagnostics for a range of neurodegenerative diseases.

Our co-founder, the late Dr K M Seng, was passionate about helping people. His drive was simply to do something positive with this science and make a difference to the millions of people affected by neurodegenerative disease, where still there are no cures.



“ My father, Dr K M Seng's vision and dream for TauRx was to help people, we must continue this important legacy. ”

Dr Seng Shay Way
MANAGING DIRECTOR, TAURX

From my years as a clinical practitioner and specialist old age psychiatrist, I have seen first-hand how dementia cuts into people's lives and cuts into their family's lives. Clinical trials are critical to take science from the lab bench to a point where we can impact meaningfully. The patients are the bedrock of everything that we do. It is for them; it is with them that all of this work is conducted.

With a growing and dedicated research team based in Aberdeen, we have focused our research on tau pathology in Alzheimer's and related diseases. It has always been our duty, mission, and motivating force to do this research for the millions of people affected by dementia. As the numbers impacted by diseases causing dementia increase, it is essential we continue to work towards finding a breakthrough that is effective, safe and accessible to patients around the world.

The time for tau is now.

Professor Claude M. Wischik
CO-FOUNDER AND
EXECUTIVE CHAIRMAN, TAURX



About us

- > Founded in Singapore in 2002
- > Dedicated research and operations based in Aberdeen, Scotland
- > Led by Professor Claude Wischik to find an effective treatment for brain neurodegeneration caused by the misfolding of tau and other proteins

Values



Role of tau in Alzheimer's disease


In 1906, Alois Alzheimer first described a neurological illness involving dementia and the accumulation of tau and amyloid proteins in the brain.

Over the next century, research confirmed that aggregation of tau and amyloid are the hallmark pathologies of AD.

Tau is an essential protein in neurons:

- > Supports healthy neuronal structure and function
- > Stabilizes microtubules, which help support neuronal structure and transport nutrients and other essential substances for signaling between neurons

Normal tau protein stabilises microtubules in neurons, essential for healthy brain function.



Why target tau?

Tau is an important target for an effective treatment for dementia

Misfolding of normal tau protein leads to tau aggregation and the formation of tau tangles, which disrupt neuronal function in the brain. This process may begin decades before any symptoms of dementia are seen. Tau pathology correlates strongly with the severity of the disease and its progression.

TauRx is developing a potential treatment for Alzheimer's disease targeting this pathological process. It belongs to a class of drugs known as Tau Aggregation Inhibitors (TAIs). TAIs act by preventing the formation of, and dissolving, tau aggregates in the brain, thereby preserving normal tau function, which is essential for a healthy brain.


TauRx has completed the phase 3 clinical trial, LUCIDITY to establish clinical efficacy and safety of our lead compound. Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate.

Pipeline potential:

Our lead compound is formulated to target aggregates of abnormal fibres of tau, TDP-43, or synuclein proteins that form inside nerve cells in the brain that damage and ultimately kill neurons in several different neurodegenerative disorders.

We intend to research the following indications in addition to Alzheimer's disease:

- > Frontotemporal Dementia
- > Parkinson's Disease
- > Dementia with Lewy Bodies
- > Progressive Supranuclear Palsy
- > Chronic Traumatic Encephalopathy (CTE)



The global context


One of the world's greatest unmet medical needs

Epidemic



Every 3 seconds
someone in the world
develops dementia

139 million



Estimated growth in
number of people with
dementia from 2019-2050

Impact



The total estimated annual worldwide cost of dementia is over US\$ 1.3 trillion. This figure is forecast to rise to US\$ 2.8 trillion by 2030

Alzheimer's disease

is the most common cause of dementia and accounts for **50%-75%** of all cases




Approximately three quarters of people with dementia globally have not received a diagnosis




If dementia was a country, it would be the **14th** largest economy



Timeline of key TauRx milestones




For over three decades, we have achieved significant milestones in our tau pathology research



Accelerating dementia diagnosis

Understanding the patient journey



Globally, Alzheimer Disease International estimates that 75% of people with dementia are not diagnosed – around 41 million.

It can take years to move from recognising symptoms, to seeing a healthcare professional, to finally receiving a diagnosis. Potential explanations for this are wait times for diagnostic tools such as PET scans and a possible reluctance to diagnose and be diagnosed.

Digitising diagnosis

TauRx has collaborated with Genting Berhad to create GT Diagnostics (GTD) with the vision to change the diagnostic landscape and market in dementia by developing much-needed tools which support the early diagnosis of dementia and monitoring of its progression.

GTD's readily deployable e-platform tools can be used in the home as well-being apps, alongside professional tools for experts. The tools are designed to be made available through various service providers such as financial and professional services, personal advice and support, residential and non-residential care, and specialised dementia centres. Digital tools are key to bringing dementia diagnostics into the 21st century.

For more information visit www.gtdiag.com.



Why is diagnosis important?

“ The AD population desperately needs progress in diagnostics to secure wide access to future therapies. At TauRx, our focus is on delivering a successful late phase clinical trial in AD. Yet we also fully appreciate the necessity of early, accurate diagnostic tools that are simple to administer. We know there are bottlenecks in the diagnostic pathway for patients due to lengthy wait times for specialist scans, and this will be exacerbated in the event of a therapeutic breakthrough, when patients will have greater incentive to secure a diagnosis and seek treatment. ”

Professor Claude M. Wischik
CO-FOUNDER, CHAIRMAN AND CHIEF EXECUTIVE
AT TAURX

“ The common conception is that because there is no cure, diagnosis is unhelpful. But when you speak to people with the disease, they often say they were relieved and grateful when a diagnosis was made because they could suddenly understand what's going on. ”

Professor Bjoern Schelter
CEO GT DIAGNOSTICS AND CHIEF ANALYTICS OFFICER
AT TAURX

TauRx UK leadership



Professor Claude Wischik

CO-FOUNDER, CHAIRMAN AND CHIEF EXECUTIVE

Professor Wischik is a board-certified psychiatrist and Chair in Mental Health at the University of Aberdeen. He was appointed to his current position as Professor of Old Age Psychiatry at the University of Aberdeen in 1995.

Along with his scientific research team, he pioneered the early-stage research into tau aggregation inhibitors (TAIs) developed to target the tau pathology of Alzheimer's disease and similar neurodegenerative conditions. The results of foundational research showed promise and TauRx was founded in 2002 to continue the work towards the development of an effective treatment for the disease.

The company remains closely linked to the University of Aberdeen to this day and its strong research capability has been built through long-term cooperative relationships with multiple academic institutions around the world.

He has authored more than 150 scientific papers in the field of AD and the company has over 900 granted patents and additional pending applications covering the work of the team supporting the first tau-based treatment for AD and related neurodegenerative disorders.

“It’s crystal clear to me that the greater good is served by doing my best to bring this to fruition. ”




Professor John Storey

HEAD OF TECHNICAL

Professor Storey holds the Chair of Pharmaceutical Industrial Chemistry at the University of Aberdeen and specialises in synthetic organic chemistry with over 100 publications in this area.

He has collaborated with Professor Wischik and Dr Charles Harrington for 20 years and is co-inventor on 17 patent applications. He heads a team of 26 research chemists with experience in synthesis and analytical chemistry. This team has synthesised TauRx's portfolio of drug candidates and is responsible for their chemical scale-up, analysis, formulation, and pipeline development.

“The idea of an alzheimer’s drug to me was a great application of organic chemistry and Claude’s innovative and flexible approach is very different to the standard. ”



Dr Charles Harrington

HEAD OF NON-CLINICAL DEVELOPMENT AND CHIEF SCIENTIFIC OFFICER

Dr Harrington has extensive research experience in neurodegenerative diseases, is author of more than 100 publications and co-inventor on 15 patent applications in this area.

He has collaborated with Professor Wischik for over 30 years. He leads a neurobiology group of over 20 research scientists with expertise in cellular and molecular neurobiology, protein structural analyses, and animal behaviour and neuropathology. He is based in academic centres at the Universities of Aberdeen and Sussex in the UK and the Mossakowski Medical Research Institute in Warsaw, Poland.

“Through an understanding of the basis of the science behind diseases, we can resolve complexity and provide a treatment for debilitating neurodegenerative disorders. ”



Dr Glenn Corr

CHIEF OPERATING OFFICER AND CHIEF BUSINESS OFFICER

Dr Corr joined TauRx in 2020 and is accountable for running all company operations and overseeing the active development of future commercialisation options subject to the outcome of TauRx's current phase 3 trial. He has an active role in TauRx financing and investment opportunities and oversight of company structure to optimise the ability to leverage the extensive IP portfolio and facilitate deal options.

His background encompasses 25 years' experience in engineering, commercial and operational roles in high risk, capital intensive industries. He has previously served as Operations Director of EnQuest, Asset and HSEQ Director, and Commercial Manager for Maersk, and a Principal Consultant at DNV. He holds a PhD in Systems Engineering, an MBA, is a Fellow of the Institute of Directors and is on the Opportunity North East (ONE) Life Sciences board.

“Having witnessed the devastating impact of Alzheimer's at a very personal level, I am dedicated to supporting TauRx's mission to pursue a disease modifying treatment that could make a very real and positive impact to so many lives. Having the opportunity to play a very small part in this critical mission is a real privilege. ”




Dr Sonya Miller

HEAD OF MEDICAL AFFAIRS AND MEDICAL OVERSIGHT LEAD

Dr Miller is a Specialist Anaesthetist, having worked as a Consultant Anaesthetist for 25 years.

She entered pharmaceutical research when she began working as a Sub Investigator and Principal Investigator in London, focusing on Alzheimer's disease. She joined TauRx in 2018 as Medical Oversight Lead, responsible for patient safety in our trials. In her additional role as Head of Medical Affairs, Dr Miller is responsible for relationships with external stakeholders and leads the information and education delivery resulting from TauRx's research programmes.

“We are at a point where dementia research is part of a world-changing moment in clinical trials and medicine. All the research is very welcomed to contribute towards finding a disease modifying treatment for Alzheimer's, which affects so many millions of people worldwide. ”



Registered Office:

3 Shenton Way
#21-04 Shenton House
Singapore 068805
Republic of Singapore
info@taurx.com

UK Office:

395 King Street
Aberdeen
AB24 5RP
United Kingdom
www.taurx.com

Working **together** to diagnose
and treat the **world's**
greatest unmet medical need

